Nurix Therapeutics Inc
NASDAQ:NRIX

Watchlist Manager
Nurix Therapeutics Inc Logo
Nurix Therapeutics Inc
NASDAQ:NRIX
Watchlist
Price: 12.08 USD -0.49% Market Closed
Market Cap: 921m USD
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Average
N/A
Revenue
Forecast
N/A
Operating Income
Forecast
N/A
Net Income
Forecast
N/A

Wall Street
Price Targets

NRIX Price Targets Summary
Nurix Therapeutics Inc

Wall Street analysts forecast NRIX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for NRIX is 30.84 USD with a low forecast of 16.16 USD and a high forecast of 43.05 USD.

NRIX Lowest Forecast
Wall Street Target
16.16 USD
34% Upside
NRIX Average Forecast
Wall Street Target
30.84 USD
155% Upside
NRIX Highest Forecast
Wall Street Target
43.05 USD
256% Upside
Lowest
Price Target
16.16 USD
34% Upside
Average
Price Target
30.84 USD
155% Upside
Highest
Price Target
43.05 USD
256% Upside
Nurix Therapeutics Inc Competitors:
Price Targets
VCYT
Veracyte Inc
60% Upside
ALNY
Alnylam Pharmaceuticals Inc
9% Upside
INCY
Incyte Corp
13% Upside
I
086890
Isu Abxis Co Ltd
93% Upside
VCYT
Veracyte Inc
60% Upside
ALNY
Alnylam Pharmaceuticals Inc
9% Upside
INCY
Incyte Corp
13% Upside
I
086890
Isu Abxis Co Ltd
93% Upside
300653
Yantai Zhenghai Bio-Tech Co Ltd
32% Upside
BSLN
Basilea Pharmaceutica AG
95% Upside
PYC
PYC Therapeutics Ltd
190% Upside
Y
002675
Yantai Dongcheng Biochemicals Co Ltd
4% Upside

Revenue
Forecast

Revenue Estimate
Nurix Therapeutics Inc

For the last 5 years the compound annual growth rate for Nurix Therapeutics Inc's revenue is 12%. The projected CAGR for the next 3 years is 15%.

12%
Past Growth
15%
Estimated Growth
Estimates Accuracy
-9%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Nurix Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
4%
Average Beat
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Nurix Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-35%
Average Miss
What are analyst estimates?

See Also

Summary
NRIX intrinsic value, competitors valuation, and company profile.
DCF Valuation
NRIX stock valuation using Discount Cash Flow valuation method.
Relative Valuation
NRIX stock valuation using valuation multiples.
Wall Street Estimates
NRIX price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
NRIX stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is NRIX's stock price target?
Price Target
30.84 USD

According to Wall Street analysts, the average 1-year price target for NRIX is 30.84 USD with a low forecast of 16.16 USD and a high forecast of 43.05 USD.

What is Nurix Therapeutics Inc's Revenue forecast?
Projected CAGR
15%

For the last 5 years the compound annual growth rate for Nurix Therapeutics Inc's revenue is 12%. The projected CAGR for the next 3 years is 15%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 259,300+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.